Smith+Nephew (NYSE: SNN) has officially secured FDA clearance for its innovative stemless anatomical total shoulder implant, part of the Aetos system. This new product answers the rising demand for anatomical total shoulder replacements, providing a compact solution that allows for more efficient surgical procedures.
The design of the Aetos Stemless prioritizes metaphyseal fixation and stability, making use of an inlay collar, cruciate fins, and a titanium porous coating to stimulate biological adhesion. With a fully operational launch of the Aetos shoulder system in the U.S. earlier this year, Smith+Nephew has expanded its range with additional FDA approvals. Initially granted FDA clearance in June 2023, the Aetos system has fortified the company’s upper extremity offerings.
Headquartered in London, Smith+Nephew crafted the Aetos to enhance patients’ mobility and alleviate arthritic shoulder discomfort. The system includes the Aetos Meta Stem, designed for stability while preserving bone integrity and maintaining natural anatomy structure. The latest stemless implant broadens the portfolio, streamlining the transition from Stemless to Meta Stem configurations.
“Aetos Stemless signifies a major leap forward in shoulder arthroplasty and highlights our dedication to achieving superior patient outcomes and advancing orthopedic surgery,” said Craig Gaffin, the president of Global Orthopaedics at Smith+Nephew. “With Aetos Stemless, we’re further able to tailor surgeries, equipping surgeons with tools to facilitate optimal patient recoveries and assist them in experiencing ‘Life Unlimited.'”
This development is a boon for the orthopedic firm, which has recently implemented significant layoffs within the organization.